Biohaven Ltd.

Biohaven Ltd.

BHVNNYSE / NASDAQHealthcareSmall cap

$12.39-$1.26 (-9.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.7B
P/E
-2.3x
EV / EBITDA
-2.4x
Revenue
$0.00
ROCE
-222.2%

+28.7% over the last year

Biohaven Ltd. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+4.9%
3M
-8.2%
6M
+40.0%
1Y
+28.7%
5Y
Short history
  • A period is left blank when the price history is shorter than the period.

52-week range

Day change -$1.26 (-9.2%) from $13.65 to $12.39 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BHVN, bought on each weekday since 2022.

News & filings

What Biohaven filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 739 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 3.18 times current liabilities.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.

Read moreShow less

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Sector
Healthcare
Shares outstanding
132.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.7B
P/E
-2.3x
P/B
33.0x
EV / EBITDA
-2.4x
52-week high
$16.95
52-week low
$8.09

Profitability

ROE
-1418.8%
ROCE
-222.2%
ROIC
-551.7%
ROA
-163.7%

Growth

Revenue
$0.00
Net profit growth, 1Y
-12.7%
Free cash flow
-$610.2M

Solvency

Current ratio
3.18
Debt / Equity
5.47
Debt / Assets
0.63
CFO / Net profit
0.82
Cash / Market cap
13.4%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Biohaven Ltd. revenue and net profit by fiscal year
Biohaven Ltd. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$570.3M
FY2023$0.00-$408.2M
FY2024$0.00-$846.4M
FY2025$0.00-$738.8M

Cash flows

FY2025: -$609.4M from operations, -$610.2M free after investment (dashed).

Biohaven Ltd. operating and free cash flow by fiscal year
Biohaven Ltd. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$297.7M-$338.8M
FY2023-$331.7M-$334.8M
FY2024-$582.5M-$586.5M
FY2025-$609.4M-$610.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$735.5M
Net profit
-$738.8M
Cash from operations
-$609.4M
Free cash flow
-$610.2M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$735.5M-$738.8M-$610.2M-1418.8%—-12.7%

Monthly returns

Month-by-month returns of BHVN across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$451.4M
Liabilities$399.4M
Equity$52.1M
Paid-in capital$194.0M
Retained earnings-$2.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BHVN highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Biohaven Ltd., SELLAS Life Sciences Group, Inc., Sionna Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Biohaven Ltd.BHVNthis company$1.7B-2.3x33.0x-1418.8%-2.4x
SELLAS Life Sciences Group, Inc.SLS$1.8B-66.2x25.1x-37.9%-60.4x
UFP Technologies, Inc.UFPT$1.7B25.4x4.1x16.1%16.8x
Agios Pharmaceuticals, Inc.AGIO$1.7B-4.1x1.4x-34.6%-3.6x
Sionna Therapeutics, Inc.SION$1.7B-22.7x5.6x-24.5%-18.7x
Taysha Gene Therapies, Inc.TSHA$1.7B-15.5x6.9x-44.1%-13.4x
Novavax, Inc.NVAX$1.7B3.8x-13.1x-344.7%3.4x
Addus HomeCare CorporationADUS$1.7B17.5x1.5x8.8%11.2x
GeneDx Holdings Corp.WGS$1.7B-79.5x5.4x-6.8%138.2x
Peer median—-9.8x4.8x-29.6%-0.1x

Year-to-date ROI

BHVN since 1 January, against earlier years.

Historical volatility

BHVN's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$745.4M
Research and developmentResearch And Development$635.1M
Total expensesTotal Expenses$745.4M
Pretax incomePretax Income-$737.4M

Learn while you research

Academy chapters picked for Biohaven Ltd. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 5.47 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →